Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCVS Caremark Opzelura Prior Auth Coverage | OpenPa…
    Ask Trek AI about this page
    CurrentCVS CaremarkPolicy 5018-C

    Initial Prior Authorization with Quantity Limit Opzelura

    Customize your policy alerts

    Sign up for cvs_caremark Policy 5018-C alerts

    Get alerted when Policy 5018-C changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs initial and continuation prior authorization for Opzelura cream, including coverage criteria for atopic dermatitis and nonsegmental vitiligo and applicable quantity limits. It applies to adult and pediatric patients meeting the condition-specific age, clinical response, body surface area, and treatment-use requirements.

    Policy Summary
    PayerCVS Caremark
    PolicyInitial Prior Authorization with Quantity Limit Opzelura
    Policy CodePolicy 5018-C
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionFor initial therapy, identify the indication and demonstrate that the applicable age, non-combination, body surface area, and indication-specific criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2FDA-approved indications covered
    60 g/21 daysStandard quantity limit
    20% BSAAtopic dermatitis BSA limit
    10% BSAVitiligo BSA limit

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12 months
    Continuation approval duration

    Coverage Criteria

    Atopic Dermatitis Initial Therapy

    Covered when ALL of the following are met.

    • Treatment and patient requirements: The requested drug is not prescribed with therapeutic biologics, other Janus kinase (JAK) inhibitors, or potent immunosuppressants such as azathioprine or cyclosporine; the request is for an adult or pediatric patient 2 years of age or older; and the requested drug will not be applied to affected areas greater than 20 percent body surface area (BSA).Age >= 2 years; BSA <= 20%
    • ONE of the following topical therapy circumstances

      • The patient's disease is not adequately controlled with other topical prescription therapies, such as a medium- or higher-potency topical corticosteroid or topical calcineurin inhibitor.
      • Other topical prescription therapies, such as a medium- or higher-potency topical corticosteroid or topical calcineurin inhibitor, are not advisable.
    • Additional quantity condition

      • No additional quantity is requested.
      • Additional quantities are requested and the requested drug is prescribed to treat a body surface area requiring more than 60 grams per 28 days.>60 g per 28 days when additional quantities are requested

    Nonsegmental Vitiligo Initial Therapy

    Covered when ALL of the following are met.

    • Treatment and patient requirements: The requested drug is not prescribed with therapeutic biologics, other Janus kinase (JAK) inhibitors, or potent immunosuppressants such as azathioprine or cyclosporine; the request is for an adult or pediatric patient 12 years of age or older; and the requested drug will not be applied to affected areas greater than 10 percent body surface area (BSA).Age >= 12 years; BSA <= 10%
    • Additional quantity condition

      • No additional quantity is requested.
      • Additional quantities are requested and the requested drug is prescribed to treat a body surface area requiring more than 60 grams per 28 days.>60 g per 28 days when additional quantities are requested

    Atopic Dermatitis Continuation Therapy

    Covered when ALL of the following are met.

    • Treatment and patient requirements: The requested drug is not prescribed with therapeutic biologics, other Janus kinase (JAK) inhibitors, or potent immunosuppressants such as azathioprine or cyclosporine; the request is for an adult or pediatric patient 2 years of age or older; and the requested drug will not be applied to affected areas greater than 20 percent body surface area (BSA).Age >= 2 years; BSA <= 20%
    • Clinical response: The patient has achieved or maintained a positive clinical response, evidenced by improvement in or resolution of signs or symptoms such as erythema (redness), edema (swelling), xerosis (dry skin), erosions, excoriations (evidence of scratching), oozing and crusting, lichenification (epidermal thickening), or pruritus (itching).
    • Additional quantity condition

      • No additional quantity is requested.

    Nonsegmental Vitiligo Continuation Therapy

    Covered when ALL of the following are met.

    • Treatment and patient requirements: The requested drug is not prescribed with therapeutic biologics, other Janus kinase (JAK) inhibitors, or potent immunosuppressants such as azathioprine or cyclosporine; the request is for an adult or pediatric patient 12 years of age or older; and the requested drug will not be applied to affected areas greater than 10 percent body surface area (BSA).Age >= 12 years; BSA <= 10%
    • Clinical response: The patient has achieved or maintained a positive clinical response, evidenced by improvement such as meaningful repigmentation.
    • Additional quantity condition

      • No additional quantity is requested.

    Opzelura must not be used in combination with therapeutic biologics, other Janus kinase (JAK) inhibitors, or potent immunosuppressants such as azathioprine or cyclosporine. This restriction applies to initial and continuation therapy for both atopic dermatitis and nonsegmental vitiligo.

    Initial Therapy Criteria

    Atopic Dermatitis Initial

    Authorization may be granted when ALL of the following criteria are met for atopic dermatitis initial therapy.

    • ONE of the following topical therapy circumstances

      • The patient's disease is not adequately controlled with other topical prescription therapies, such as a medium- or higher-potency topical corticosteroid or topical calcineurin inhibitor.
      • Other topical prescription therapies, such as a medium- or higher-potency topical corticosteroid or topical calcineurin inhibitor, are not advisable.
    • Additional quantity condition

      • No additional quantity is requested.

    Continuation Criteria

    Atopic Dermatitis Continuation

    Authorization may be granted when ALL of the following criteria are met for atopic dermatitis continuation therapy.

    • Clinical response: The patient has achieved or maintained a positive clinical response, evidenced by improvement in or resolution of signs or symptoms such as erythema (redness), edema (swelling), xerosis (dry skin), erosions, excoriations (evidence of scratching), oozing and crusting, lichenification (epidermal thickening), or pruritus (itching).
    • Additional quantity condition

      • No additional quantity is requested.
      • Additional quantities are requested and the requested drug is prescribed to treat a body surface area requiring more than 60 grams per 28 days.>60 g per 28 days when additional quantities are requested

    Clinical Thresholds and Quantity Requirements

    Atopic Dermatitis BSA Limit
    Maximum affected areaNot greater than 20% body surface area (BSA)
    Applies toAtopic dermatitis initial and continuation therapy
    Additional quantitiesIf requested, treatment must require more than 60 grams per 28 days
    Nonsegmental Vitiligo BSA Limit
    Maximum affected areaNot greater than 10% body surface area (BSA)
    Applies toNonsegmental vitiligo initial and continuation therapy
    Additional quantities

    Provider Documentation and Decision Points

    Prior Authorization

    Initial Indication and Eligibility

    For initial authorization, document whether Opzelura is prescribed for topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis or for topical treatment of nonsegmental vitiligo, and confirm the applicable age and affected-area requirements.

    • Atopic dermatitis: patient is an adult or pediatric patient 2 years of age or older; treatment is for mild to moderate disease in a non-immunocompromised patient; affected areas must not exceed 20% BSA.
    • Nonsegmental vitiligo: patient is an adult or pediatric patient 12 years of age or older; affected areas must not exceed 10% BSA.
    • For either indication, document that the request meets all applicable initial-therapy criteria before authorization.
    Documentation Required

    Continuation Response

    For continuation authorization, document that the patient has achieved or maintained a positive clinical response to Opzelura while continuing to meet the applicable indication, age, combination-therapy, BSA, and quantity requirements.

    Policy Background

    Opzelura (ruxolitinib) cream is covered for topical treatment of mild to moderate atopic dermatitis in non-immunocompromised adults and pediatric patients 2 years of age and older when topical prescription therapies are inadequate or not advisable. Coverage also applies to topical treatment of nonsegmental vitiligo in adults and pediatric patients 12 years of age and older. The policy limits the treated area to no more than 20% BSA for atopic dermatitis and no more than 10% BSA for nonsegmental vitiligo, and excludes use with therapeutic biologics, other JAK inhibitors, or potent immunosuppressants.

    Definitions

    BSA
    BSA meansBody surface area affected by the condition
    ApplicationThe area to which Opzelura will be applied
    Condition-specific limitsAtopic dermatitis: not greater than 20% BSA; nonsegmental vitiligo: not greater than 10% BSA
    FDA-Approved Indication
    Atopic dermatitisTopical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adults and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable
    Nonsegmental vitiligoTopical treatment in adult and pediatric patients 12 years of age and older

    Step Therapy Requirement

    StepRequirementExamples
    1Other topical prescription therapies must have been inadequate to control the patient's atopic dermatitis or must not be advisable.Medium- or higher-potency topical corticosteroid or topical calcineurin inhibitor

    Quantity Limits

    Standard Opzelura Quantity Limit
    21-day limit60 grams per 21 days
    63-day limit180 grams per 63 days
    Fill-period useThe 21-day duration is used for a 28-day fill period, and the 63-day duration is used for an 84-day fill period to allow time for refill processing
    Larger BSA: Nonsegmental Vitiligo
    21-day limit180 grams per 21 days
    63-day limit540 grams per 63 days
    Applicable conditionLarger body surface area for nonsegmental vitiligo
    Policy Summary
    PayerCVS Caremark
    PolicyInitial Prior Authorization with Quantity Limit Opzelura
    Policy CodePolicy 5018-C
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionFor initial therapy, identify the indication and demonstrate that the applicable age, non-combination, body surface area, and indication-specific criteria are met.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation CriteriaClinical Thresholds and Quantity RequirementsProvider Documentation and Decision PointsPolicy BackgroundDefinitionsStep Therapy RequirementQuantity Limits
  1. Additional quantities are requested and the requested drug is prescribed to treat a body surface area requiring more than 60 grams per 28 days.>60 g per 28 days when additional quantities are requested
  2. Additional quantities are requested and the requested drug is prescribed to treat a body surface area requiring more than 60 grams per 28 days.>60 g per 28 days when additional quantities are requested
    Additional quantities are requested and the requested drug is prescribed to treat a body surface area requiring more than 60 grams per 28 days.>60 g per 28 days when additional quantities are requested

    Nonsegmental Vitiligo Initial

    Authorization may be granted when ALL of the following criteria are met for nonsegmental vitiligo initial therapy.

    • Additional quantity condition

      • No additional quantity is requested.
      • Additional quantities are requested and the requested drug is prescribed to treat a body surface area requiring more than 60 grams per 28 days.>60 g per 28 days when additional quantities are requested

    Nonsegmental Vitiligo Continuation

    Authorization may be granted when ALL of the following criteria are met for nonsegmental vitiligo continuation therapy.

    • Clinical response: The patient has achieved or maintained a positive clinical response, evidenced by improvement such as meaningful repigmentation.
    • Additional quantity condition

      • No additional quantity is requested.
      • Additional quantities are requested and the requested drug is prescribed to treat a body surface area requiring more than 60 grams per 28 days.>60 g per 28 days when additional quantities are requested
    If requested, treatment must require more than 60 grams per 28 days
    Additional Quantity Threshold
    ThresholdMore than 60 grams per 28 days
    Applies whenAdditional quantities are requested
    Covered conditionsAtopic dermatitis and nonsegmental vitiligo
    • Atopic dermatitis: document improvement in or resolution of signs or symptoms such as erythema, edema, xerosis, erosions, excoriations, oozing and crusting, lichenification, or pruritus.
    • Nonsegmental vitiligo: document meaningful repigmentation or other positive clinical response.
    • Continuation patients must remain at least 2 years old for atopic dermatitis or at least 12 years old for nonsegmental vitiligo.
    Step Therapy

    Prior Topical Therapy for Atopic Dermatitis

    For atopic dermatitis, document inadequate control with, or unsuitability of, other topical prescription therapies before requesting Opzelura.

    • Other topical therapies may include a medium- or higher-potency topical corticosteroid or a topical calcineurin inhibitor.
    • Document either that these therapies did not adequately control the disease or that they are not advisable for the patient.
    Denial Risk

    Prohibited Combination Therapy

    Do not request or continue Opzelura concurrently with therapeutic biologics, other Janus kinase (JAK) inhibitors, or potent immunosuppressants.

    • The restriction applies to both atopic dermatitis and nonsegmental vitiligo.
    • Examples of potent immunosuppressants include azathioprine and cyclosporine.
    Denial Risk

    Age, BSA, or Response Criteria Not Met

    Authorization is not supported when the applicable age, BSA, or continuation-response requirements are not met. Confirm the indication-specific thresholds and document the required response for continuation requests.

    • Atopic dermatitis: deny or do not authorize if the patient is younger than 2 years, affected areas exceed 20% BSA, or continuation documentation does not show achieved or maintained positive clinical response.
    • Nonsegmental vitiligo: deny or do not authorize if the patient is younger than 12 years, affected areas exceed 10% BSA, or continuation documentation does not show positive clinical response such as meaningful repigmentation.
    • For initial atopic dermatitis requests, lack of inadequate control with or unsuitability of other topical prescription therapies is also an eligibility failure.
    Billing Rule

    Additional Quantity Requirements

    If additional quantities are requested, document that the treated BSA requires more than 60 grams per 28 days and apply the indication- and age-specific quantity limits. New starts should be filled one month at a time rather than as a 3-month supply.

    • Standard quantity limit: 60 grams per 21 days or 180 grams per 63 days.
    • For larger BSA in nonsegmental vitiligo: 180 grams per 21 days or 540 grams per 63 days.
    • For larger BSA in atopic dermatitis, pediatric patients 2–11 years: 120 grams per 21 days or 360 grams per 63 days.
    • For larger BSA in atopic dermatitis, patients 12 years and older: 240 grams per 21 days or 720 grams per 63 days.
    • The 21-day limit is used for a 28-day fill period and the 63-day limit for an 84-day fill period to allow refill processing; do not fill 3-month supplies for new starts.
    DrugOpzelura (ruxolitinib cream)
    Larger BSA: Pediatric Atopic Dermatitis
    21-day limit120 grams per 21 days
    63-day limit360 grams per 63 days
    Applicable patientsAtopic dermatitis patients 2 to 11 years of age with larger body surface area
    Larger BSA: Atopic Dermatitis Age 12 and Older
    21-day limit240 grams per 21 days
    63-day limit720 grams per 63 days
    Applicable patientsAtopic dermatitis patients 12 years of age and older with larger body surface area